A regulatory note for accuracy: neither BPC-157 nor TB-500 is approved by Health Canada for therapeutic use in humans, and both are listed on the World Anti-Doping Agency (WADA) Prohibited List BPC-157 under Section S0 (non-approved substances) and TB-500 under S2
2026 May 20
This is why when you go on a diet, your body fights you
Research in this area is pretty hit or miss though, and as usual Im reluctant to take animal studies and extrapolate them to humans
Liraglutide-loaded nanoparticles have been found in preclinical or early-stage studies to improve patient adherence, enhance bioavailability, sustain glucose-lowering effects, reduce food intake and body weight, and prevent cardiomyopathy and lipotoxicity
These shifts require slightly more thought, though semaglutide weekly dosing makes it far less complicated than managing a twice-daily medication